The Anlon Healthcare IPO has opened for subscription on August 26, 2025, and will close on August 29, 2025. With a price band of ₹86 to ₹91 per share and a total issue size of ₹121.03 crores, the IPO has attracted significant attention from both institutional and retail investors. In this article, we will track the subscription status, Grey Market Premium (GMP), listing expectations, and overall IPO analysis, so investors can make an informed decision on whether to subscribe or avoid.
IPO Issue Details
- IPO Date: August 26, 2025 to August 29, 2025
- Price Band: ₹86 to ₹91 per share
- Lot Size: 164 shares (Minimum investment ₹14,924)
- Total Issue Size: ₹121.03 Crores (1.33 crore shares)
- Issue Type: 100% Fresh Issue
- Listing: BSE, NSE
- Tentative Listing Date: September 3, 2025
IPO Reservation:
- QIB: Not less than 75%
- NII: Not less than 15%
- Retail: Not more than 10%
You can check our earlier article about detailed Review on Anlon Healthcare IPO.
Anlon Healthcare IPO Subscription Status
Subscription status is a crucial indicator of investor demand. (We will update this section as daily subscription data is released by exchanges.)
As of Day 1 (August 26, 2025):
- QIBs: [To be updated]
- NIIs: [To be updated]
- Retail: [To be updated]
- Total Subscription: [To be updated]
Note: A strong subscription in QIB and NII categories usually signals higher listing gains.
Grey Market Premium (GMP) Update
The Grey Market Premium (GMP) reflects the unofficial premium at which IPO shares are traded before listing. As of the latest update:
- Anlon Healthcare IPO GMP: Around ₹20-25 per share
- Estimated Listing Price: ₹111 to ₹116 (against the upper band of ₹91)
- Expected Listing Gain: 20-25%
👉 A stable or rising GMP till the closing date generally indicates strong listing potential.
Factors Supporting Strong Listing
- Attractive Valuation – P/E of 14.26x vs. industry average of 28x.
- Strong Financial Performance – PAT grew from ₹5.82 Cr in FY23 to ₹11.96 Cr (10M FY25).
- Diversified Product Portfolio – 65 commercialized products and multiple DMF approvals.
- Positive GMP Trends – Indicating healthy investor interest.
Key Risks That May Impact Listing
- High Competition – Larger API players like Divi’s Laboratories enjoy stronger brand recognition.
- Low Retail Quota – With only 10% reserved, retail demand may overshoot availability, leading to disappointment in allotment.
- Regulatory Hurdles – Pharma business is highly dependent on timely approvals and compliance.
Check Anlon Healthcare IPO – Key Strenghts, Risks and Longterm Prospects
Listing Expectations
Considering the attractive pricing, strong fundamentals, and current GMP trends, the IPO is likely to list at a premium of 20–25% over the issue price. However, sustained performance post-listing will depend on quarterly results, regulatory updates, and execution of expansion plans.
Conclusion
The Anlon Healthcare IPO is gaining traction with investors due to its strong financials, competitive valuations, and growing market presence. GMP trends and expected oversubscription suggest healthy listing gains. For investors looking for short-term listing profits, this IPO appears attractive. Long-term investors should weigh the business strengths against risks like regulatory dependence and working capital needs.
FAQs
1. What is the Anlon Healthcare IPO GMP today?
Currently, the GMP is around ₹20-25 per share.
2. When will Anlon Healthcare IPO shares be listed?
Tentative listing date is September 3, 2025.
3. How much is the retail quota in Anlon Healthcare IPO?
Not more than 10% of the total issue size.
4. What is the expected listing gain of Anlon Healthcare IPO?
Analysts expect around 20-25% listing gain based on current GMP.
5. Is Anlon Healthcare IPO good for short-term investors?
Yes, subscription demand and GMP indicate strong listing prospects.
6. What is the IPO price band?
₹86 to ₹91 per share.
7. How can investors apply for this IPO?
Through ASBA in net banking or via UPI on trading apps like Zerodha, Groww, and Paytm Money.
Disclaimer:
This article is for informational purposes only and should not be considered as investment advice or a recommendation to subscribe/avoid any IPO. Investors should carefully read the Red Herring Prospectus (RHP) and consult their financial advisor before making any investment decision. The author and website are not responsible for any financial gains or losses incurred by acting on this information.
- Anlon Healthcare IPO Subscription Status, GMP and Listing Expectations - August 23, 2025
- Anlon Healthcare IPO – Key Strengths, Risks and Long-Term Prospects Investors Should Know - August 23, 2025
- Anlon Healthcare IPO – Review, Date, Price, GMP, Analysis – Should You Subscribe or Avoid? - August 23, 2025
Discover more from Myinvestmentideas.com
Subscribe to get the latest posts sent to your email.